Convalescent Plasma in Hospitalized COVID-19 Patients: a Single Center Experience
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.
详细描述
Inclusion criteria:
Adult inpatients with a severe form of COVID-19 have been enrolled, with at least one of the following inclusion criteria: 1) tachypnea with respiratory rate (RR) > 30 breaths/min; 2) oxygen saturation (SpO2) ≤ 93% at rest and in room air; 3) partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤ 200 mmHg, 4) radiological picture and/or chest CT scan showing signs of interstitial disease and/or rapid progression of lung involvement.
Primary outcome:
Overall mortality at 28 days after hospitalization
Secondary outcome:
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients admitted for severe COVID-19
排除标准
- •< 18 years
- •participation in any other clinical trial of an experimental treatment for COVID-19
研究者
Massimo Franchini
Director Immunohematology and Transfusion Center
Azienda Socio Sanitaria Territoriale di Mantova